Hence, targeting FOXM1 using TST, a natural FOXM1 inhibitor that appears to abrogate immune evasion and reduce tumor growth, is a new potential treatment strategy for PD‐L1‐mediated immune evasion in lung cancer cells. Here, CD274 is linked to lung carcinoma.